Robotic man cyborg face representing artificial intelligence concept 3D rendering

What Experts say

What experts say


“Modiblast is a very promising approach to address residual leukemic cells and convert them to ‘leukemia-derived DC’ that activate the patient’s immune system against blasts”
Prof. Dr. Hans-Jochem Kolb, the pioneer of stem cell transplantation in Germany


“The Modiblast approach may entail substantial advantages compared to other therapies in the state-of-the-art” 
Prof. Dr. Dr. Ulrike Köhl, Specialist for Cell Therapy and Immunobiology


“We believe that in vivo therapy with response modifiers can become a promising treatment approach for leukemia patients”
Prof. Dr. A. Borkhard, Director Clinic f. Pediatric Oncology, Hematology, and Clinical Immunology, Düsseldorf